First human trial of SUPLEXA cells targets Hard-to-Treat cancers
Disease control
Completed
This early-stage trial tested a new therapy called SUPLEXA in 46 adults with advanced solid tumors or blood cancers that had spread. SUPLEXA is made from a patient's own immune cells, which are processed in a lab to become more active against cancer. The main goal was to check sa…
Phase: PHASE1 • Sponsor: Alloplex Biotherapeutics Inc • Aim: Disease control
Last updated Jun 26, 2026 18:11 UTC